Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis.

Arends S, van der Veer E, Groen H, Houtman PM, Jansen TL, Leijsma MK, Bijzet J, Limburg PC, Kallenberg CG, Spoorenberg A, Brouwer E.

J Rheumatol. 2011 Aug;38(8):1644-50. doi: 10.3899/jrheum.101128. Epub 2011 Jun 1.

PMID:
21632677
[PubMed - indexed for MEDLINE]
2.

Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.

Woo JH, Lee HJ, Sung IH, Kim TH.

J Rheumatol. 2007 Aug;34(8):1753-9. Epub 2007 Jun 15.

PMID:
17610317
[PubMed - indexed for MEDLINE]
3.

Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.

Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC Jr.

J Rheumatol. 2005 Oct;32(10):1911-7.

PMID:
16206346
[PubMed - indexed for MEDLINE]
4.

[Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].

Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.

Zhonghua Yi Xue Za Zhi. 2006 Sep 19;86(35):2451-4. Chinese.

PMID:
17156669
[PubMed - indexed for MEDLINE]
5.

[Clinical study of etanercept for treating ankylosing spondylitis].

Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1349-51. Chinese.

PMID:
18753057
[PubMed - indexed for MEDLINE]
Free Article
6.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

PMID:
19877087
[PubMed - indexed for MEDLINE]
Free Article
7.

[Serum metalloproteinase-3 levels in assessing efficacy of Etanercept in patients with ankylosing spondylitis].

Wang QH, Zhang SZ, Xue J, Wu HX.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010 Jul;39(4):409-14. Chinese.

PMID:
20731042
[PubMed - indexed for MEDLINE]
8.

Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.

Wendling D, Cedoz JP, Racadot E.

Joint Bone Spine. 2008 Oct;75(5):559-62. doi: 10.1016/j.jbspin.2008.01.026.

PMID:
18674944
[PubMed - indexed for MEDLINE]
9.

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.

Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK.

Rheumatology (Oxford). 2002 May;41(5):484-9.

PMID:
12011369
[PubMed - indexed for MEDLINE]
Free Article
10.

Etanercept in the longterm treatment of patients with ankylosing spondylitis.

Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van Den Bosch F, van der Heijde D, van der Linden S, Wajdula J.

J Rheumatol. 2009 Jun;36(6):1256-64. doi: 10.3899/jrheum.081033. Epub 2009 May 1. Erratum in: J Rheumatol. 2010 Oct;37(10):2198.

PMID:
19411393
[PubMed - indexed for MEDLINE]
11.

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.

de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.

Ann Rheum Dis. 2009 Apr;68(4):531-5. doi: 10.1136/ard.2008.089979. Epub 2008 Mar 28.

PMID:
18375542
[PubMed - indexed for MEDLINE]
12.

Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.

Chou CT, Tsai CY, Liang TH, Chang TM, Lai CH, Wei CC, Chen KH, Lin SC, Yu CL, Liou LB, Luo SF, Lee CS, Hsue YT, Huang CM, Chen JH, Lai NS, Cheng HH, Cheng TT, Lai HM, Tsai WC, Yen JH, Lu LY, Chang CP.

Mod Rheumatol. 2010 Dec;20(6):580-7. doi: 10.1007/s10165-010-0334-2. Epub 2010 Aug 4.

PMID:
20683633
[PubMed - indexed for MEDLINE]
13.

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group.

Arthritis Rheum. 2003 Nov;48(11):3230-6.

PMID:
14613288
[PubMed - indexed for MEDLINE]
Free Article
14.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2003 Jun;48(6):1667-75.

PMID:
12794835
[PubMed - indexed for MEDLINE]
Free Article
15.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

PMID:
21689401
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2005 Dec 15;53(6):856-63.

PMID:
16342093
[PubMed - indexed for MEDLINE]
Free Article
17.

Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.

Park MC, Chung SJ, Park YB, Lee SK.

Scand J Rheumatol. 2008 May-Jun;37(3):173-8. doi: 10.1080/03009740801898608. Erratum in: Scand J Rheumatol. 2008 Nov-Dec;37(6):492. Jung, SJ [corrected to Chung, SJ].

PMID:
18465450
[PubMed - indexed for MEDLINE]
18.

Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.

Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT.

Rheumatology (Oxford). 2006 Apr;45(4):414-20. Epub 2005 Nov 15.

PMID:
16287916
[PubMed - indexed for MEDLINE]
Free Article
19.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Gorman JD, Sack KE, Davis JC Jr.

N Engl J Med. 2002 May 2;346(18):1349-56.

PMID:
11986408
[PubMed - indexed for MEDLINE]
Free Article
20.

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.

Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.

Rheumatology (Oxford). 2005 Mar;44(3):342-8. Epub 2004 Nov 23. Erratum in: Rheumatology (Oxford). 2005 Apr;44(4):569.

PMID:
15561737
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk